Preparation and characterization of liposomes containing a lipophilic cisplatin derivative for clinical use

Roman Perez-Soler, K. Francis, S. Al-Baker, F. Pilkiewicz, A. R. Khokhar

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Cis-bis-neodecanoato-trans-R,R-l,2 diaminocyclohexane platinum(II) (NDDP) is a lipophilic cisplatin derivative that has been formulated entrapped in multilamellar liposomes composed of dimyristoylphosphatidyl choline (DMPC) and dimyristoylphosphatidyl glycerol (DMPG). A phase I clinical study with liposome-entrapped NDDP (L-NDDP) administered i.v. every 4 weeks has been recently completed. L-NDDP was synthesized, manufactured, and reconstituted for clinical use in our laboratories. L-NDDP was prepared as a lyophilized powder containing the NDDP and the phospholipids (NDDP-lipid weight ratio 1: 15; DMPC-DMPG molar ratio 7: 3). The liposome suspension was obtained on the day of use just before administration to the patients by adding normal saline (final concentration 1 mg NDDP/ml) and shaking in a water-bath shaker at room temperature according to an established protocol. A total of 54 batches of lyophilized L-NDDP were prepared. Physical appearance, phospholipid content and integrity, and elemental platinum content were determined in all batches and found to be reproducible. All batches contained < 0.24ng/ml endotoxin. The amount of residual organic solvents was < 0.05 per cent. In all reconstituted doses, drug entrapment was > 90 per cent, and the proportion of liposomes measuring < 5 μm was < 20 per cent. Our results show that reproducible batches of liposomal preparations of new compounds can be prepared in the laboratory facilities of academic institutions, thus allowing for early clinical trials with novel therapeutic agents.

Original languageEnglish (US)
Pages (from-to)41-54
Number of pages14
JournalJournal of Microencapsulation
Volume11
Issue number1
DOIs
StatePublished - 1994
Externally publishedYes

Fingerprint

choline
Liposomes
glycerols
Cisplatin
platinum
Derivatives
preparation
shaking
integrity
lipids
baths
proportion
Phospholipids
Choline
Platinum
Glycerol
room temperature
water
Baths
Powders

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Colloid and Surface Chemistry
  • Physical and Theoretical Chemistry
  • Bioengineering
  • Organic Chemistry
  • Chemical Engineering(all)
  • Chemistry (miscellaneous)
  • Pharmacology

Cite this

Preparation and characterization of liposomes containing a lipophilic cisplatin derivative for clinical use. / Perez-Soler, Roman; Francis, K.; Al-Baker, S.; Pilkiewicz, F.; Khokhar, A. R.

In: Journal of Microencapsulation, Vol. 11, No. 1, 1994, p. 41-54.

Research output: Contribution to journalArticle

Perez-Soler, Roman ; Francis, K. ; Al-Baker, S. ; Pilkiewicz, F. ; Khokhar, A. R. / Preparation and characterization of liposomes containing a lipophilic cisplatin derivative for clinical use. In: Journal of Microencapsulation. 1994 ; Vol. 11, No. 1. pp. 41-54.
@article{b17a37c8423245fca9154ad872fe047a,
title = "Preparation and characterization of liposomes containing a lipophilic cisplatin derivative for clinical use",
abstract = "Cis-bis-neodecanoato-trans-R,R-l,2 diaminocyclohexane platinum(II) (NDDP) is a lipophilic cisplatin derivative that has been formulated entrapped in multilamellar liposomes composed of dimyristoylphosphatidyl choline (DMPC) and dimyristoylphosphatidyl glycerol (DMPG). A phase I clinical study with liposome-entrapped NDDP (L-NDDP) administered i.v. every 4 weeks has been recently completed. L-NDDP was synthesized, manufactured, and reconstituted for clinical use in our laboratories. L-NDDP was prepared as a lyophilized powder containing the NDDP and the phospholipids (NDDP-lipid weight ratio 1: 15; DMPC-DMPG molar ratio 7: 3). The liposome suspension was obtained on the day of use just before administration to the patients by adding normal saline (final concentration 1 mg NDDP/ml) and shaking in a water-bath shaker at room temperature according to an established protocol. A total of 54 batches of lyophilized L-NDDP were prepared. Physical appearance, phospholipid content and integrity, and elemental platinum content were determined in all batches and found to be reproducible. All batches contained < 0.24ng/ml endotoxin. The amount of residual organic solvents was < 0.05 per cent. In all reconstituted doses, drug entrapment was > 90 per cent, and the proportion of liposomes measuring < 5 μm was < 20 per cent. Our results show that reproducible batches of liposomal preparations of new compounds can be prepared in the laboratory facilities of academic institutions, thus allowing for early clinical trials with novel therapeutic agents.",
author = "Roman Perez-Soler and K. Francis and S. Al-Baker and F. Pilkiewicz and Khokhar, {A. R.}",
year = "1994",
doi = "10.3109/02652049409040437",
language = "English (US)",
volume = "11",
pages = "41--54",
journal = "Journal of Microencapsulation",
issn = "0265-2048",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Preparation and characterization of liposomes containing a lipophilic cisplatin derivative for clinical use

AU - Perez-Soler, Roman

AU - Francis, K.

AU - Al-Baker, S.

AU - Pilkiewicz, F.

AU - Khokhar, A. R.

PY - 1994

Y1 - 1994

N2 - Cis-bis-neodecanoato-trans-R,R-l,2 diaminocyclohexane platinum(II) (NDDP) is a lipophilic cisplatin derivative that has been formulated entrapped in multilamellar liposomes composed of dimyristoylphosphatidyl choline (DMPC) and dimyristoylphosphatidyl glycerol (DMPG). A phase I clinical study with liposome-entrapped NDDP (L-NDDP) administered i.v. every 4 weeks has been recently completed. L-NDDP was synthesized, manufactured, and reconstituted for clinical use in our laboratories. L-NDDP was prepared as a lyophilized powder containing the NDDP and the phospholipids (NDDP-lipid weight ratio 1: 15; DMPC-DMPG molar ratio 7: 3). The liposome suspension was obtained on the day of use just before administration to the patients by adding normal saline (final concentration 1 mg NDDP/ml) and shaking in a water-bath shaker at room temperature according to an established protocol. A total of 54 batches of lyophilized L-NDDP were prepared. Physical appearance, phospholipid content and integrity, and elemental platinum content were determined in all batches and found to be reproducible. All batches contained < 0.24ng/ml endotoxin. The amount of residual organic solvents was < 0.05 per cent. In all reconstituted doses, drug entrapment was > 90 per cent, and the proportion of liposomes measuring < 5 μm was < 20 per cent. Our results show that reproducible batches of liposomal preparations of new compounds can be prepared in the laboratory facilities of academic institutions, thus allowing for early clinical trials with novel therapeutic agents.

AB - Cis-bis-neodecanoato-trans-R,R-l,2 diaminocyclohexane platinum(II) (NDDP) is a lipophilic cisplatin derivative that has been formulated entrapped in multilamellar liposomes composed of dimyristoylphosphatidyl choline (DMPC) and dimyristoylphosphatidyl glycerol (DMPG). A phase I clinical study with liposome-entrapped NDDP (L-NDDP) administered i.v. every 4 weeks has been recently completed. L-NDDP was synthesized, manufactured, and reconstituted for clinical use in our laboratories. L-NDDP was prepared as a lyophilized powder containing the NDDP and the phospholipids (NDDP-lipid weight ratio 1: 15; DMPC-DMPG molar ratio 7: 3). The liposome suspension was obtained on the day of use just before administration to the patients by adding normal saline (final concentration 1 mg NDDP/ml) and shaking in a water-bath shaker at room temperature according to an established protocol. A total of 54 batches of lyophilized L-NDDP were prepared. Physical appearance, phospholipid content and integrity, and elemental platinum content were determined in all batches and found to be reproducible. All batches contained < 0.24ng/ml endotoxin. The amount of residual organic solvents was < 0.05 per cent. In all reconstituted doses, drug entrapment was > 90 per cent, and the proportion of liposomes measuring < 5 μm was < 20 per cent. Our results show that reproducible batches of liposomal preparations of new compounds can be prepared in the laboratory facilities of academic institutions, thus allowing for early clinical trials with novel therapeutic agents.

UR - http://www.scopus.com/inward/record.url?scp=0028044636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028044636&partnerID=8YFLogxK

U2 - 10.3109/02652049409040437

DO - 10.3109/02652049409040437

M3 - Article

C2 - 8138874

AN - SCOPUS:0028044636

VL - 11

SP - 41

EP - 54

JO - Journal of Microencapsulation

JF - Journal of Microencapsulation

SN - 0265-2048

IS - 1

ER -